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Purpose: To investigate the cerebrospinal fluid (CSF) proteome of patients with preeclampsia
(PE) and normotensive pregnant women, in order to provide a better understanding of brain
involvement in PE.
Experimental design: Ninety-eight CSF samples (43 women with PE and 55 normotensive
controls) were analyzed by LC–MS/MS proteome profiling. CSF was obtained during the
spinal puncture before caesarean delivery.
Results: Eight proteins were higher abundant and 17 proteins were lower abundant in patients
with PE. The most significantly differentially abundant protein was protein AMBP (alpha-1-
microglobulin/bikunin precursor). This finding was validated by performing an ELISA experi-
ment (p = 0.002).
Conclusions and clinical relevance: The current study showed a clear difference between the
protein profiles of CSF from patients with PE and normotensive pregnant women. Protein
AMBP is a precursor of a heme-binding protein that counteracts the damaging effects of
free hemoglobin, which may be related to the presence of free hemoglobin in CSF. Protein
levels showed correlations with clinical symptoms during pregnancy and postpartum. To our
knowledge, this is the first LC–MS/MSproteome profiling study on a unique set of CSF samples
from (severe) preeclamptic patients and normotensive pregnant women.
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1 Introduction
Worldwide, 2–8% of all pregnancies are complicated by
preeclampsia (PE), a major cause of maternal and fetal mor-
bidity and mortality [1–3]. The disease presents as general
endothelial damage and hence a multiorgan disorder, affect-
ing the placenta, the mother’s liver, kidneys, clotting system,
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Clinical Relevance
This LC–MS/MS proteome profiling study on a
unique set of cerebrospinal fluid (CSF) samples
from (severe) patients with preeclampsia (PE) and
normotensive pregnant women. We found a clear
difference between the protein profiles of CSF
from patients with PE and normotensive preg-
nant controls, of which protein AMBP (alpha-
1-microglobulin/bikunin precursor) was the most
significantly differentially abundant protein. This
finding may be related to the presence of free
hemoglobin in the CSF of both normotensive and hy-
pertensive women and is suggested to be related to
an altered BBB permeability during pregnancy. How-
ever, the function of the BBB is complex and how
this exactly functions during human pregnancy and
PE needs to be further elucidated.
and heart. In severe cases of PE the maternal CNS can be
involved as well, which may result in major cerebrovascular
complications such as eclampsia and stroke. Interestingly,
PE may also lead to long-term brain pathology such as cog-
nitive impairment and stroke [4–6]. Brain complications of
PE are suggested to be the result of a disturbed cerebral
autoregulatory response to the increased blood pressure in
combination with endothelial cell dysfunction [7]. Due to dis-
ruption of the blood–brain barrier (BBB), inflammatory cells
and fluid penetrate the brain, causing oedema and cell death
[8–11]. The endothelial cells of the BBB differ from those
in peripheral tissues. They have a low rate of endocytosis
and are coupled by tight junctions to restrict the amount of
paracellular fluid. These functions ensure that not all blood
constituents can pass freely into the extracellular space in the
CNS [12].
We hypothesize that PE is associated with an abnormal
adaptation of the BBB to the changed physiological and im-
munological state of pregnancy. The aim of this study was
to investigate the cerebrospinal fluid (CSF) proteome of pa-
tients with PE and normotensive pregnant women by using
high-resolution MS.
2 Material and methods
Pregnant women of 18 years and older who underwent a cae-
sarean delivery were recruited. Approval for the study was
obtained from the Erasmus University Medical Centre Re-
search Ethics Board (MEC 2007–086). After written informed
consent a CSF sample (1 mL) was collected during the spinal
anaesthesia procedure. The needle used during the spinal
puncture was a 25 Gauge atraumatic needle. The CSF sample
was collected before anaesthetics were administered. Within
1 h the CSF samples were centrifuged and cells and debris
were discarded. The CSF was aliquoted and stored immedi-
ately at −20C and within 8 h at −80C. Cases were defined
as patients with PE who were admitted on the antenatal ward
and in need of a Caesarean delivery. PE was defined as sys-
tolic blood pressure140 mmHg or diastolic blood pressure
90 mm Hg on at least two occasions 4 h apart after 20
wk of gestation or postpartum in combination with protein-
uria (300 mg/24 h or protein/creatinine ratio  0.3 mg)
[13, 14]. Controls were pregnant women without PE in need
for a Caesarean delivery. Clinical data were obtained from
the medical records of the study participants. General char-
acteristics were statistically compared between study groups
by using Mann–Whitney U tests data for (not normally dis-
tributed) continuous data and Chi-square tests or Fisher’s
exact test for categorical data. Clinical postnatal data were
available up to 1 year postpartum. Neurological symptoms
postpartum were defined as complaints of headache, visual
disturbances, concentration problems, and other cognitive
complaints.
Samples were processed in two batches, using the CSF di-
gestion and MS measurement protocol previously published
[15]. In brief, from each CSF sample, 20 L was added to
20 L of 0.2% Rapigest (Waters, Milford, MA) in 50 mM
ammonium bicarbonate buffer. After 30 min incubation pe-
riods with 1,4-dithiothreitol (60C) and, subsequently, iodoac-
etamide (37C), 6 L 0.1 g/L gold-grade trypsin (Promega,
Madison, WI)/3 mM Tris-HCl (pH 8.0) was added to each
sample. The samples were incubated overnight at 37C. To
adjust the pH of the digest to pH <2, TFA was added to the
mixture prior to the final incubation step at 37C for a dura-
tion of 45 min to stop the enzymatic digestion reaction. Sub-
sequently, the samples were measured alternating between
PE and control samples.
MS measurements were performed on a Ultimate 3000
nano LC system (Dionex, Germering, Germany) online cou-
pled to a hybrid linear ion trap/Orbitrap MS (LTQ Orbitrap
XL; Thermo Fisher Scientific, Germany). One microliter di-
gest (i.e. 0.4 L CSF) was loaded on to a C18 trap column
(C18 PepMap, 300 m id × 5 mm, 5 m particle size,
100 A˚ pore size; Dionex, The Netherlands) and desalted for
10 min using a flow rate of 20 L/min 0.1% TFA. Then the
trap column was switched online with the analytical column
(PepMap C18, 75 m id × 150 mm, 3 m particle and 100
A˚ pore size; Dionex, The Netherlands) and peptides were
eluted with following binary gradient: 0–25% solvent B in
120 min and 25–50% solvent B in further 60 min, where
solvent A consist of 2% ACN and 0.1% formic in water and
solvent B consists of 80% ACN and 0.08% formic acid in
water. Column flow rate was set to 300 nL/min. For MS
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detection a data-dependent acquisition method was used:
high-resolution survey scan from 400 to 1800 Th. was per-
formed in an Orbitrap (value of target of automatic gain
control AGC 106, resolution 30 000 at 400 m/z; lock mass
was set to 445.120025 u (protonated (Si(CH3)2O)6)). Based on
this survey scan the five most intensive ions were consecu-
tively isolated (AGC target set to 104 ions) and fragmented
by collision-activated dissociation applying 35% normalized
collision energy in the linear ion trap. After precursors were
selected for MS/MS, they were excluded for further MS/MS
spectra for 3 min.
The raw data were preprocessed using the Progene-
sis LC-MS software package (version 4.0, Nonlinear Dy-
namics, Newcastle-upon-Tyne, UK). Peptides were identified
and assigned to proteins by exporting features, for which
MS/MS spectra were recorded, using the Bioworks software
package (version 3.2; Thermo Fisher Scientific; peak pick-
ing by Extract_msn, default settings). The resulting .mgf
file was submitted to Mascot (version 2, Matrix Science,
London, UK) for identification to interrogate the UniProt
database (release 2013_07; taxonomy: Homo sapiens, con-
taining 20 265 sequences). Only ions with charge states
between +2 and +8 were considered and only proteins
with at least two unique peptides (Mascot ions sore >25,
(i.e. a peptide probability cut off value of 0.01)) assigned to
themwere accepted as true identifications.Modifications: car-
bamidomethylation of cysteine was set as fixed and oxidation
of methionine as variable modification, allowing a maximum
of two missed cleavages. Mass tolerance for precursor ions
was set to 10 ppm and for fragment ions at 0.5 Da. The
Mascot search results were imported into the Progene-
sis software to link the identified peptides to the detected
abundances of these peptides. The peptide abundances were
normalized to the total ion current to compensate for experi-
mental variations using an algorithm available in the analysis
software. Subsequently the data were exported in Excel for-
mat.
The raw abundances of all identified peptides were com-
pared between the groups of samples by performing an un-
paired two-tailed t-test on all individual peptides. Proteins
were deemed to be significantly differentially abundant be-
tween the groups if they passed a set of three separate crite-
ria: (1) 50% or more of the peptides of the protein had a low
p-value (p < 0.05); (2) 30% of the peptides of the protein had
a very low p-value (p < 0.01); (3) 75% or more of the peptides
of the protein must be altered in the same direction between
the groups [15–17]. We determined the statistical background
level by performing a permutation test using all samples and
all identified peptides. The random permutation test, on the
dataset with randomized sample group assignment, was re-
peated 1000 times through which the resulting thresholds
were saved.
Following the results of this experiment three valida-
tion experiments were performed. A commercially avail-
able ELISA for in vitro quantitative measurements of fetal
hemoglobin (HbF;Cloud-cloneCorp.,USA) and anELISA for
in vitro quantitative measurement of protein AMBP (alpha-
1-microglobulin/bikunin precursor, LifeSpan BioSciences,
Inc., USA) were performed. The AMBP concentrations
were calculated by generating a four-parameter logistic stan-
dard curve (CurveExpert v1.3, 2013, Supporting Information
Fig. 1).
Another validation experiment for A1M (alpha-1-
microglobulin), a derivative protein ofAMBP,was performed.
A1M was measured with an in-house RIA method, as previ-
ously described by Olsson et al. [18]. Briefly, the analysis
was performed by mixing goat antiserum against human
A1M (diluted 1:6000) with 125I-labeled A1M (0.05 pg/mL)
and unknown patient samples or calibrator A1M concentra-
tions. After incubating the samples overnight at RT, antibody-
bound antigen was precipitated, after which the 125I-activity
of the pellets was measured in a Wallac Wizard 1470 gamma
counter (Perkin Elmer Life Sciences). Statistical compari-
son of AMBP and A1M values was performed by using the
Student’s t-test and ANOVA. Not normally distributed data
(AMBP) were log transformed before testing. Correlations for
gestational age at sampling and with neurological symptoms
were tested by using Pearson’s correlation test.
3 Results
3.1 LC–MS/MS proteome profiling
CSF samples from 43 patients with PE and 55 normotensive
pregnantwomenwere obtained for proteomics analysis.Most
general characteristics did not significantly differ between the
groups, except for parity, gestational age at sampling, PE in a
previous pregnancy, and a caesarean delivery in the obstetric
history (Table 1). As a result of the definition of PE, women
with PE had a higher blood pressure (median 170/110 mm
Hg) than normotensive controls (median 122/77 mm Hg).
More detailed clinical information about the cases, divided
by early-onset PE (EOPE) and late-onset PE is available in
Supporting Information Table 1.
A total of 3473 peptides were identified, corresponding to
457 unique proteins. Of the 3473 peptides 317 peptides had
p-values below 0.01. The number of background hits obtained
by permutationwas 49.6± 51.3, indicating that the number of
peptides found with low p-values in the true analysis was well
above expected background levels (Supporting Information
Fig. 2).
Of the 457 proteins, 25 were differentially abundant be-
tween cases and controls by using the above mentioned se-
lection criteria. Eight proteins were higher abundant and 17
proteins were lower abundant in the CSF from patients with
PE (Table 2). Subtype analyses for HELLP syndrome (where
HELLP is hemolysis, elevated liver enzymes and low platelet
count), severe PE, and EOPE did not result in additional dif-
ferentially abundant proteins.
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Table 1. General characteristicsa)
Preeclampsia (n = 52) Normotensive controls (n = 58) p-value*
Maternal age (years) 32 (29–36) 34 (31–36) 0.318
Ethnicity 0.511
Dutch 38 (73.1%) 38 (66.7%)
Other Western 0 (0%) 2 (3.5%)
Non Western 14 (26.9%) 17 (29.8%)
Current pregnancy
Nulliparous 32 (61.5%) 21 (36.2%) <0.05
Gestational age sampling (days) 215 (196–237) 270 (264–272) <0.05
Preconception BMI (kg/m2) 25.5 (21.6–29.4) 23.8 (21.1–29.1) 0.245
Smoking (during pregnancy) 2 (5.0%) 3 (5.4%) 0.302
Highest systolic blood pressure (mm Hg) 170 (160–180) 120 (118–134) <0.05
Highest diastolic blood pressure (mm Hg) 110 (100–110) 77 (70–80) <0.05
Gestational diabetes 1 (1.9%) 3 (5.2%) 0.620
Twin pregnancy 3 (5.8%) 1 (1.7%) 0.342
Medical history
Chronic hypertension 13 (25%) 1 (1.8%) <0.05
Diabetes mellitus type 1 2 (3.8%) 1 (1.7%) 0.602
Diabetes mellitus type 2 1 (1.9%) 0 0.473
Obstetric history
Recurrent miscarriages 2 (3.8%) 1 (1.7%) 0.602
PE in previous pregnancy 12 (23.1%) 5 (8.6%) <0.05
Previous caesarean delivery 10 (19.2%) 26 (44.8%) <0.05
Phenotypes preeclampsia
HELLP 15 (28.8%) N/A
Early-onset preeclampsia 40 (76.9%) N/A
Severe preeclampsia 45 (86.5 %) N/A
Clinical symptoms
Headache 30 (58.8%) 7 (12.1) <0.05
Visual complaints 10 (20.0%) 3 (5.2%) <0.05
Upper abdominal pain 24 (48.0%) 3 (5.2%) <0.05
Nausea 5 (9.8%) 2 (3.4%) 0.249
General discomfort 8 (15.7%) 8 (13.8%) 0.780
Dyspnea 8 (15.7%) 2 (3.4%) <0.05
Child characteristicsb)
Birth weight (g) 1190 (900–1860) 3390 (2875–3690) <0.05
Birth weight percentile <0.05
<10th percentile 14 (25.5%) 4 (6.9%)
10th–90th percentile 40 (72.7%) 40 (69.0%)
>90th percentile 1 (1.8%) 14 (24.1%)
Fetal gender ratio (male:female) 0.67 0.66 0.970
Neonatal death 3 (2.7%) 3 (2.7%) 1.000
Intrauterine fetal death 0 1 (0.9%) 1.000
a)Data are presented as n (%) or median with IQR.
b)Due to two twin pregnancies n = 113.
*For comparisons between groups Mann–Whitney U tests, Chi-square tests, and Fisher’s exact tests were used.
3.2 Validation experiments
The most significantly differentially abundant protein was
protein AMBP. A validation experiment (ELISA) in 19 ran-
domly chosen normotensive pregnant controls and 20 pa-
tients with PE of the same study group was performed. The
level of protein AMBP was significantly higher in patients
with PE versus normotensive controls (15.24 (interquartile
range (IQR) 11.42–23.76)) ng/mL versus 10.88 (IQR 7.74–
12.92) ng/mL, p = 0.002, Table 3 and Fig. 1). When we sub-
divided the cases in EOPE and late-onset PE, a significant
differencewas found in theAMBP level of patientswith EOPE
and normotensive women (17.92 (IQR 12.21–3.17) ng/mL
versus 10.88 (IQR 7.74–12.92) ng/mL, p = 0.001).
Protein AMBP is a precursor of A1M and bikunin. We
additionally quantified the A1M level in 47 CSF samples of
patients with PE and 52 CSF samples of normotensive con-
trols from the same study group (in-house RIA method).
A1M was significantly higher in PE compared to controls
(0.35 (±0.1) ng/mL versus 0.27 (±0.14) ng/mL, p = 0.012).
We found no correlation of A1M levels with gestational age at
sampling.
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Table 2. Differentially abundant proteins in CSF of patients with preeclampsiaa)
Higher abundant proteins (accession number) Peptides
(n)
p-valueb)
<0.01 (%)
p-valueb)
<0.05 (%)
Peptides changed
in the same
direction (%)
Fold
change
(PE/CO)
1. Protein AMBP (P02760) 10 100 100 100 1.80
2. Alpha-1-acid glycoprotein 1 (P02763) 12 58 67 83 1.54
3. Alpha-1-antichymotrypsin (P01011) 17 53 71 93 1.44
4. Retinol-binding protein 4 (P02753) 11 45 55 89 1.44
5. Insulin-like growth factor 2 (P01344) 3 33 100 100 1.47
6. Lumican (P51884) 3 33 67 100 1.54
7. Histidine-rich glycoprotein (P04196) 9 33 56 91 2.10
8. Alpha-1B-glycoprotein (P04217) 13 31 69 82 1.27
Lower abundant proteins (accession number) Peptides
(n)
p-valueb)
<0.01 (%)
p-valueb)
<0.05 (%)
Peptides changed
in the same
direction (%)
Fold
change
(PE/CO)
1. Brain acid soluble protein 1 (P80723) 7 86 86 100 0.64
2. Cadherin-13 (P55290) 6 83 83 100 0.68
3. Glucosidase 2 subunit beta (P14314) 3 67 67 100 0.80
4. Neurosecretory protein VGF (O15240) 24 63 71 100 0.67
5. Ephrin type-A receptor 4 (P54764) 7 57 71 100 0.67
6. V-set and transmembrane
domain-containing protein 2A
(B5MCX6)
4 50 75 100 0.54
7. Neurocan core protein (O14594) 4 50 75 75 0.78
8. Amyloid-like protein 1 (P51693) 11 45 55 82 0.76
9. Neuronal cell adhesion molecule
(Q92823)
27 44 59 96 0.75
10. Pyruvate kinase PKM (P14618) 9 44 56 78 0.76
11. Chromogranin-A (P10645) 19 42 79 94 0.67
12. Protein kinase C-binding protein NELL2
(Q99435)
17 41 71 100 0.70
13. Neural cell adhesion molecule (O15394) 8 38 63 87 0.82
14. Cartilage acidic protein 1 (Q9NQ79) 16 38 56 81 0.93
15. Seizure 6-like protein (Q9BYH1) 8 38 50 87 0.89
16. Limbic system-associated membrane
protein (Q13449)
6 33 50 100 0.79
17. Neuroserpin (Q99574) 6 33 50 83 0.83
CO, control.
a)Selection criteria of statistically significant differentially abundant proteins were: >3 peptides identified, >30% with a p-value of <0.01,
>50% with a p-value of <0.05, >75% of the peptides changed in the same direction.
b)t-test comparison between the groups.
Table 3. Quantification of protein AMBP and A1M*
CO (n = 19) PE (n = 20) LOPE (n = 7) EOPE (n = 13)
Concentration AMBP, median (IQR) ng/mL 10.88 (7.74–12.92) 15.24(11.42–23.76) 13.95 (9.65–19.48) 17.92 (12.21–33.17)
Log of concentration AMBP, mean (SD) 2.30 (± 0.41) 2.87 (± 0.62)a) 2.62 (± 0.40) 3.03 (± 0.70)c)
CO (n = 52) PE (n = 47) LOPE (n = 11) EOPE (n = 36)
Concentration A1M, mean (SD) ng/mL 0.27 (± 0.14) 0.35 (±0.18)b) 0.29 (± 0.13) 0.36 (± 0.19)d)
CO, control; LOPE, late-onset preeclampsia.
*Comparisons between groups with T-test and ANOVA with post hoc Bonferroni
a) p = 0.002 (PE vs. CO).
b) p = 0.012 (PE vs. CO).
c) p = 0.001 (EOPE vs. CO).
d) p = 0.011 (EOPE vs. CO).
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Figure 1. Boxplots of AMBPandA1M levels **p = 0.001 (EOPE vs. CO). *p = 0.011 (EOPE vs. CO). CO, control; LOPE, late-onset preeclampsia.
Free hemoglobin was identified in the CSF in both
cases and controls. In order to exclude that the presence
of hemoglobin was caused by a traumatic puncture, we re-
peated our experiment in exactly the same manner in four
other normotensive pregnant women. We collected the first,
fifth, and tenth drop of CSF. Again, free hemoglobin proved
to be present in these samples, regardless of the order of the
aliquots collected. When the presence of hemoglobin in the
CSF samples is due to contamination, we would expect the
abundance of hemoglobin the highest in the first drop before
decreasing to the lowest amount in the tenth drop.
In order to find out if the free hemoglobin detected was
either of maternal or fetal origin an ELISA for HbF was
performed. The detection limit of this immunoassay was
0.55 ng/mL. We were not able to detect HbF in the CSF
samples, because the resulting values were lower than the
detection limit of the assay.
3.3 Clinical symptoms during pregnancy
In order to investigate the clinical implications of these find-
ings we studied neurological symptoms of the study partici-
pants and their relation to AMBP and A1M levels.
In the PE group 58.8% of the participants reported com-
plaints of headache, compared to 12.1% of the normotensive
pregnant women. Twenty percent of the patients with PE re-
ported visual complaints, which was 5.2% in the group of
normotensive pregnant women (Table 1).
A positive correlationwas found between visual symptoms
and AMBP level in the whole group (p < 0.01) (Supporting
Information Fig. 3).
In the subgroup of severe PE, AMBP and A1M levels tend
to be lower in women who reported neurological symptoms
than in women without neurological symptoms (ln AMBP:
2.9 ± 0.75 vs. 3.2 ± 0.34, A1M: 0.33 ± 0.20 ng/mL vs. 0.41
± 0.14 ng/mL), though this difference was not statistically
significant (Supporting Information Fig. 4).
3.4 Clinical symptoms postpartum
A total of 37.3% percent of PE patients (all severe PE) re-
ported neurological symptoms from 6 wk to 1 year after de-
livery (Supporting Information Table 2), while none of the
normotensive women reported these symptoms during their
standard 6 wk checkup after delivery (p  0.0001). A positive
correlation was found between postnatally reported neuro-
logical symptoms and AMBP level (p < 0.05). Most reported
symptoms were concentration problems and headache. In
line with the neurological symptoms during pregnancy, a
positive correlation was also found between postnatally re-
ported neurological symptoms and AMBP level (p < 0.01)
(Supporting Information Fig. 5)
4 Discussion
The current study showed a clear difference between the pro-
tein profiles of CSF from patients with PE and normoten-
sive pregnant women. To our knowledge, this is the first
study that performed high-resolution MS on CSF samples
of pregnant women with and without PE. Normal preg-
nancy is associated with neurophysiological adaptations of
the brain, including decreased inhibitory gamma aminobu-
tyric acid type A receptor subunit expression in the cere-
bral cortex that lowers seizure threshold [19]. Studies have
previously shown that pregnancy is a state with higher neu-
ronal network excitability and a lower seizure threshold. This
may be due to high levels of neurosteroids during pregnancy
[19–22].
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In addition to this, the BBB is suggested to play an
important role in this process. Cipolla and co-workers
investigated the function of the BBB in nonpregnant ver-
sus late-pregnant rats. They found that pregnancy caused a
significant increase in BBB permeability following acute hy-
pertension [23].
4.1 Protein AMBP and free hemoglobin
Themost significantly differentially abundant protein, is pro-
tein AMBP,whichwas higher abundant in PE. ProteinAMBP
is a precursor of A1M and bikunin. A1M has been related to
pregnancy and PE in several studies. Elevated serum levels
of HbF and A1M in first trimester have been described to be
predictive of subsequent development of PE and were also
correlated with the severity of the disease [24]. In an ex-vivo
placenta perfusion experiment, free hemoglobin was shown
to damage the blood–placenta barrier by inducing oxidative
stress. Free Hb caused structural damage to the placenta,
signs of oxidative stress similar to what have been described
in the PE placenta. By adding the heme-binding protein A1M
to the system, the structural damage was prevented and leak-
age over the placenta barrier was inhibited [25, 26]. It is hy-
pothesized that the pathogenesis of PE involves an increased
expression of HbF in the placenta that due to barrier damage,
leaks into the maternal circulation, causes oxidative stress,
and further endothelial damage [26]. A1M is a heme-binding
protein that is higher abundant and counteracts the dam-
aging effects of free hemoglobin, shown to be elevated in
PE. Free Hb might cause damage to the BBB in a similar
way as described for the blood–placenta barrier. A similar
process occurs in cerebral hemorrhage in preterm infants.
Fragments of Hb cause cell death following intraventricular
hemorrhage and upregulation of heme-scavenging proteins
reduce the damage to the infants brain [27, 28]. A recent MS
study showed protein AMBP also to be elevated in plasma of
patients with PE, before the manifestation of clinical disease
[29]. Our findings are in line with these studies, which we
showed for the first time in maternal CSF. Because the brain
during this disorder is at risk for damage, these proteins may
be upregulated.
Interestingly, when we only look in the subgroup of se-
vere PE, AMBP, and A1M levels tend to be lower in women
who reported neurological symptoms than in womenwithout
neurological symptoms, taking into account that levels in PE
were still higher than those in normotensive pregnancy, al-
though this difference was not statistically significant. AMBP
and A1M are upregulated in PE, but the upregulation and
protective effect of AMBP/A1M for the CNSmay fail in cases
with severe PE who still report neurological symptoms. A
possible explanation may be that these women are not able
to oppose the toxic effects of PE properly. However, this can-
not be proved with our data, since there was no functional
study of the BBB. What makes it difficult is that PE has a
heterogeneous phenotype. The pathophysiological process in
the brain is complex and differs from patient to patient. This
may also explain the variation of AMBP and A1M levels in
the PE group.
Only a few previous studies investigated CSF of preg-
nant women by low-resolution MS [30–36]. Norwitz et al.
identified nanomolar amounts of free hemoglobin in CSF
of pregnant women (n = 22) [35]. The method of identifica-
tion used in this study was SELDI-TOF mass spectroscopy.
A significantly higher free hemoglobin concentration was
found in the CSF in patients with severe PE than in the CSF
from mild PE or controls. They stated that this toxic free
hemoglobin may have a role in the cerebrovascular injuries
seen in patients with severe PE. Although in line with the
results described by Norwitz et al., it is a remarkable find-
ing that free hemoglobin is present in CSF in all pregnant
women, as shown in the present study. From MS data of
nonpregnant healthy patients we know that CSF contains
no or a very low content of free haemoglobin. None of our
CSF samples contained macroscopically visible hemoglobin.
The needle used in our study (25 Gauge) is not expected to
cause more traumatic punctures than the needle (22 Gauge)
commonly used during lumbar punctures performed by a
neurologist. Furthermore, the total amount of proteins did
not differ from the total amount of proteins normally found
in CSF of nonpregnant subjects, which supports the idea that
the presence of free hemoglobin was not likely caused by a
traumatic puncture, but this event cannot be completely ruled
out.
4.2 Other differentially abundant proteins in CSF of
patients with PE
In this section, we will briefly describe the other differentially
abundant proteins and their possible relation to PE (Table 2).
Alpha-1-acid glycoprotein is an acute phase protein that in-
creases during inflammation and protects the endothelium.
It was previously identified as a predictive biomarker for PE
in urine [37,38]. Alpha-1-acid glycoprotein is constitutively ex-
pressed by humanmicrovascular endothelial cells [39]). Inter-
estingly, previous studies identified alpha-1-acid glycoprotein
as a protein, which alters the BBB integrity in inflammatory-
related diseases [40–42]. Alpha-1-antichymotrypsin is a high
abundant plasma protein that is synthesized by the liver and
by trophoblast cells. In previous studies, serum and urine lev-
els of this protein were significantly higher in patients with
PE. Moreover, this protein was found to be a possible pre-
dictor of PE [43, 44]. Retinol-binding protein-4 carries retinol
in the blood and is higher abundant in patients with an im-
paired glucose regulation, obesity, diabetes, polycystic ovary
syndrome, and cardiovascular disease, in fact all risk factors
for PE. One previous study showed an association with EOPE
[45], though another study did not identify significantly al-
tered serum levels in PE [46]. Also, insulin-like growth factor
2 showed a positive correlationwith PE in a prospective cohort
study [47]. Histidine-rich glycoprotein is a protein interacting
with angiogenesis and the coagulation system. It acts as a
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negative acute phase reactant and its plasma levels are re-
duced during the last trimester of pregnancy [48,49]. The last
two higher abundant proteins in the CSF were Lumican and
alpha-1-B glycoprotein. These proteins have not previously
been correlated to PE. The lower abundant proteins that were
found in PE CSF (brain acid soluble protein 1, cadherin-13,
neurosecretory proteinVGF, neurocan core protein, neuronal
cell adhesion molecule, seizure-6 like protein, limbic system
associated membrane protein, and neuroserpin) are not pre-
viously known to have an association with PE. Most of them
have a specific function in neuronal cell adhesion, neural cell
growth, and interaction. It has been reported previously that
decrease of neurological proteins is for instance observed in
multiple sclerosis.
4.3 Strengths and limitations
A major strength of our study is that a unique set of CSF
samples from (severe) preeclamptic patients and normoten-
sive pregnant women was analyzed by using high-resolution
MS. A limitation is that the cases and controls differed in
parity and gestational age. However, the difference in gesta-
tional age is unavoidable when studying severe early-onset
preeclamptic patients. Uncomplicated controls are rarely de-
livered by caesarean delivery before 37–38 gestational weeks.
Another limitation is that the finding that the CSF proteome
of patients with PE differed from normotensive controls may
be related to the fact that during the spinal puncture most of
the PE patients received intravenous administration of mag-
nesiumsulphate (77%) and nicardipine (69%), respectively,
with a neuroprotective and antihypertensive effect. Also,most
women in the PE group (77%) received antepartum corticos-
teroids for fetal lung maturation.
A third limitation is that we were not able to compare our
data with the CSF proteome of nonpregnant women. Having
CSF samples of this group would be helpful in better under-
standing the effect on the BBB of pregnancy itself. This is a
challenge for future research, since it is hard to collect these
kind of samples. From an ethical point of view, CSF of healthy
women without neurological diseases in the reproductive age
can only be collected during spinal anaesthesia procedures
for standard care. In our situation very few of these women
receive spinal anaesthesia for operative procedures.
5 Concluding remarks
There is a clear difference between the protein profiles of
CSF from patients with PE and normotensive pregnant con-
trols. The finding that free hemoglobin was present in the
CSF of both normotensive and hypertensive women may be
explained by a different BBB permeability during pregnancy.
This suggests that pregnancy itself makes the brainmore vul-
nerable to cerebral complications, which is then aggravated
in PE when protective proteins such as A1M are upregulated.
However, the function of the BBB is complex and how this
exactly functions during human pregnancy and PE needs to
be further elucidated.
StefanHansson is a founder and share-holder of A1MPharma
AB, which holds patent rights on medical uses of A1M based on
its heme-binding properties. The other authors have declared no
conflict of interest
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